Yifan Pharmaceutical Co., Ltd. (002019.SZ)
CNY 11.38
(0.53%)
CNY 11.38
(0.53%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.29 Billion CNY | 27.35% |
| 2022 | 1.01 Billion CNY | 10.32% |
| 2021 | 923.05 Million CNY | 175.46% |
| 2020 | 335.09 Million CNY | -13.43% |
| 2019 | 387.06 Million CNY | 396.01% |
| 2018 | -130.76 Million CNY | 46.9% |
| 2017 | -246.24 Million CNY | -129.63% |
| 2016 | 831.03 Million CNY | 91.2% |
| 2015 | 434.63 Million CNY | 2831.97% |
| 2014 | 14.82 Million CNY | -94.93% |
| 2013 | 292.48 Million CNY | -11.32% |
| 2012 | 329.81 Million CNY | -17.74% |
| 2011 | 400.92 Million CNY | 46.39% |
| 2010 | 273.86 Million CNY | 568.33% |
| 2009 | -58.47 Million CNY | -133.62% |
| 2008 | 173.94 Million CNY | 54.39% |
| 2007 | 112.66 Million CNY | -24.07% |
| 2006 | 148.38 Million CNY | 53.75% |
| 2005 | 96.5 Million CNY | 222.77% |
| 2004 | -78.6 Million CNY | -209.57% |
| 2003 | 71.74 Million CNY | 212.48% |
| 2002 | 22.95 Million CNY | 50.77% |
| 2001 | 15.22 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 1.44 Billion CNY | 20.18% |
| 2024 Q1 | 1.2 Billion CNY | -7.33% |
| 2024 Q3 | 1.43 Billion CNY | -48.06% |
| 2023 FY | 1.29 Billion CNY | 27.35% |
| 2023 Q2 | 1.24 Billion CNY | 12.77% |
| 2023 Q3 | 1.18 Billion CNY | -5.02% |
| 2023 Q4 | 1.29 Billion CNY | 9.83% |
| 2023 Q1 | 1.1 Billion CNY | 8.26% |
| 2022 Q1 | 1.14 Billion CNY | 23.79% |
| 2022 Q3 | 1.2 Billion CNY | -8.66% |
| 2022 FY | 1.01 Billion CNY | 10.32% |
| 2022 Q2 | 1.32 Billion CNY | 15.82% |
| 2022 Q4 | 1.01 Billion CNY | -15.76% |
| 2021 Q1 | 504.44 Million CNY | 50.54% |
| 2021 Q4 | 923.05 Million CNY | 23.63% |
| 2021 FY | 923.05 Million CNY | 175.46% |
| 2021 Q2 | 576.81 Million CNY | 14.35% |
| 2021 Q3 | 746.64 Million CNY | 29.44% |
| 2020 Q3 | 166.76 Million CNY | 88.05% |
| 2020 Q1 | 404.32 Million CNY | 4.46% |
| 2020 FY | 335.09 Million CNY | -13.43% |
| 2020 Q2 | 88.68 Million CNY | -78.07% |
| 2020 Q4 | 335.09 Million CNY | 100.94% |
| 2019 Q4 | 387.06 Million CNY | 116.06% |
| 2019 Q3 | 179.14 Million CNY | 273.92% |
| 2019 FY | 387.06 Million CNY | 396.01% |
| 2019 Q1 | 80.78 Million CNY | 161.78% |
| 2019 Q2 | -103 Million CNY | -227.51% |
| 2018 Q4 | -130.76 Million CNY | -137.18% |
| 2018 Q1 | -744.44 Million CNY | -202.32% |
| 2018 FY | -130.76 Million CNY | 46.9% |
| 2018 Q2 | -278.19 Million CNY | 62.63% |
| 2018 Q3 | 351.73 Million CNY | 226.44% |
| 2017 FY | -246.24 Million CNY | -129.63% |
| 2017 Q3 | 203.92 Million CNY | -80.24% |
| 2017 Q2 | 1.03 Billion CNY | -2.48% |
| 2017 Q1 | 1.05 Billion CNY | 27.37% |
| 2017 Q4 | -246.24 Million CNY | -220.75% |
| 2016 FY | 831.03 Million CNY | 91.2% |
| 2016 Q1 | 527.14 Million CNY | 21.29% |
| 2016 Q2 | 1.04 Billion CNY | 98.2% |
| 2016 Q4 | 831.03 Million CNY | -13.45% |
| 2016 Q3 | 960.18 Million CNY | -8.1% |
| 2015 Q4 | 434.63 Million CNY | 280.66% |
| 2015 Q3 | 114.17 Million CNY | 4943.66% |
| 2015 Q2 | -2.35 Million CNY | 96.73% |
| 2015 Q1 | -72.03 Million CNY | -585.92% |
| 2015 FY | 434.63 Million CNY | 2831.97% |
| 2014 Q4 | 14.82 Million CNY | 211.3% |
| 2014 Q3 | -13.31 Million CNY | -105.59% |
| 2014 Q1 | 297.68 Million CNY | 1.78% |
| 2014 Q2 | 238.14 Million CNY | -20.0% |
| 2014 FY | 14.82 Million CNY | -94.93% |
| 2013 FY | 292.48 Million CNY | -11.32% |
| 2013 Q4 | 292.48 Million CNY | -6.9% |
| 2013 Q3 | 314.18 Million CNY | -9.82% |
| 2013 Q2 | 348.4 Million CNY | -2.58% |
| 2013 Q1 | 357.63 Million CNY | 8.44% |
| 2012 FY | 329.81 Million CNY | -17.74% |
| 2012 Q2 | 323.14 Million CNY | -20.94% |
| 2012 Q4 | 329.81 Million CNY | -0.66% |
| 2012 Q3 | 332.01 Million CNY | 2.74% |
| 2012 Q1 | 408.72 Million CNY | 1.95% |
| 2011 Q2 | 362.1 Million CNY | 6.1% |
| 2011 Q4 | 400.92 Million CNY | 5.33% |
| 2011 Q3 | 380.64 Million CNY | 5.12% |
| 2011 Q1 | 341.3 Million CNY | 24.62% |
| 2011 FY | 400.92 Million CNY | 46.39% |
| 2010 Q2 | 170.43 Million CNY | 5265.75% |
| 2010 Q4 | 273.86 Million CNY | 23.68% |
| 2010 Q3 | 221.44 Million CNY | 29.93% |
| 2010 FY | 273.86 Million CNY | 568.33% |
| 2010 Q1 | -3.29 Million CNY | 94.36% |
| 2009 Q1 | 183.59 Million CNY | 5.55% |
| 2009 Q4 | -58.47 Million CNY | 43.05% |
| 2009 FY | -58.47 Million CNY | -133.62% |
| 2009 Q2 | 191.9 Million CNY | 4.52% |
| 2009 Q3 | -102.68 Million CNY | -153.51% |
| 2008 FY | 173.94 Million CNY | 54.39% |
| 2008 Q3 | 168.99 Million CNY | 81.57% |
| 2008 Q2 | 93.07 Million CNY | -8.85% |
| 2008 Q1 | 102.1 Million CNY | -9.37% |
| 2008 Q4 | 173.94 Million CNY | 2.93% |
| 2007 Q2 | 170.41 Million CNY | 12.01% |
| 2007 Q1 | 152.14 Million CNY | 2.54% |
| 2007 Q3 | 147.63 Million CNY | -13.37% |
| 2007 Q4 | 112.66 Million CNY | -23.69% |
| 2007 FY | 112.66 Million CNY | -24.07% |
| 2006 Q1 | 108.29 Million CNY | 12.22% |
| 2006 Q3 | 122.64 Million CNY | 2.9% |
| 2006 FY | 148.38 Million CNY | 53.75% |
| 2006 Q4 | 148.38 Million CNY | 20.98% |
| 2006 Q2 | 119.18 Million CNY | 10.06% |
| 2005 FY | 96.5 Million CNY | 222.77% |
| 2005 Q1 | -10.06 Million CNY | 87.19% |
| 2005 Q2 | 23.16 Million CNY | 330.07% |
| 2005 Q3 | 97.45 Million CNY | 320.71% |
| 2005 Q4 | 96.5 Million CNY | -0.97% |
| 2004 FY | -78.6 Million CNY | -209.57% |
| 2004 Q3 | -92.05 Million CNY | -228.55% |
| 2004 Q2 | 71.61 Million CNY | 0.0% |
| 2004 Q4 | -78.6 Million CNY | 14.61% |
| 2003 FY | 71.74 Million CNY | 212.48% |
| 2003 Q4 | 71.74 Million CNY | 0.0% |
| 2002 FY | 22.95 Million CNY | 50.77% |
| 2001 FY | 15.22 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 935.92 Million CNY | -38.56% |
| Zhejiang Zhenyuan Share Co., Ltd. | -320.75 Million CNY | 504.298% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | 580.71 Million CNY | -123.315% |
| Hubei Guangji Pharmaceutical Co., Ltd. | 520.61 Million CNY | -149.094% |
| Guangdong Jiaying Pharmaceutical Co., Ltd | -129.14 Million CNY | 1104.189% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 2.88 Billion CNY | 54.98% |
| Chongqing Lummy Pharmaceutical Co., Ltd. | -562.43 Million CNY | 330.572% |
| Boai NKY Medical Holdings Ltd. | -230.36 Million CNY | 662.938% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | -1.1 Billion CNY | 216.943% |